Endocrine Abstracts

Aim: FGF-21, is a member of the FGF family that is involved in biological processes such as embryonic development, cellular growth, morphogenesis, tissue repair, tumor growth and invasion, with mitogenic and cellular vital activity activity in the cytogenetic localization of 19q13.33. Breast cancer is the fatal disease most commonly seen in women and increasing in frequency and the relationship between hormones secreted from adipose tissue and some cancers has been shown in recent studies. Our aim in this study is to measure FGF21 levels in breast cancer patients and show their association with breast cancer.

Method: 39 patients with newly diagnosed breast cancer and 39 healthy subjects as control group were participated in the study. An extra tube blood sample was taken during the patient’s routine blood test and FGF-21 was studied by ELISA method from serum samples.

Results: The demographic and laboratory data of the newly diagnosed breast cancer patient group and the control group were compared. The control group consisted of 39 participants with a mean age of 52.49±7.02 years. In the patient group, 39 participants with a mean age of 52.15±6.21 years were included in the study. In the control group, average FGF21 measurement was 121.35±88.4 pg/ml, while FGF21 measurement in the patient group was 171±117.45 pg/ml and a significant difference was detected (P: 0.036).

Conclusion: It has been thought that FGF21 has significant and positive effects on glucose, lipid and energy metabolism as well as slowing effects on growth in cancer cells and may be used later as a biological marker for breast cancer.